BVCF

Cellenkos is a clinical-stage biotechnology company dedicated to developing and commercializing innovative allogeneic T-regulatory cell therapies aimed at treating autoimmune and inflammatory disorders. By utilizing umbilical cord blood-derived T-regulatory cells, Cellenkos seeks to create biopharmaceutical products that provide healthcare providers with effective treatment options for patients suffering from these conditions. The company's focus on early-stage clinical biotechnology positions it to address significant unmet medical needs in the field of autoimmune disease management.

The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.

Drug Farm Inc. is a biotechnology company based in Shanghai, China, specializing in the development of innovative treatments for metabolic diseases, infections, and autoimmune disorders. The company utilizes a unique platform known as IDInVivo, which integrates advanced genetic screening and artificial intelligence technologies to identify novel drug targets and expedite the drug development process. By leveraging these cutting-edge methodologies, Drug Farm aims to create first-in-class therapies that address conditions such as obesity, diabetes, hepatitis B virus (HBV), and cancer. Their approach combines insights from living animals with intact immune systems and sophisticated AI techniques, including supervised, active, and reinforcement learning, to enhance the efficiency of medicinal chemistry and improve healthcare outcomes.

Boan Biotech is a fully integrated biopharmaceutical company specializing in the development, manufacture, and commercialization of therapeutic antibodies. The company focuses on several key therapeutic areas, including oncology, metabolism, autoimmunity, and ophthalmology. While it primarily generates revenue from customers in Mainland China, Boan Biotech aims to expand its reach globally. The company is committed to delivering high-quality biologics to address unmet medical needs in these critical fields.

Seinda develops a point-of-care diagnosis platform for ophthalmic diagnosis and treatment. Seinda is committed to establishing an open ophthalmic omics platform, conducting molecular mechanism research on eye diseases, developing innovative diagnosis and treatment products, meeting clinical needs, gaining market premium, and building a world-class Chinese brand.

BioNTech is a biotechnology company based in Germany that specializes in developing innovative therapies for cancer and infectious diseases, including COVID-19. The company is known for its focus on individualized immunotherapy and has a diverse oncology pipeline that features various classes of drugs, such as mRNA-based therapeutics that encode antigens and neoantigens, as well as cytokines, antibodies, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech's notable achievement includes the commercialization of its COVID-19 vaccine, Comirnaty. Additionally, the company collaborates with several major pharmaceutical firms, enhancing its capabilities and reach in the biopharmaceutical industry.

Stealth is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. The company was founded in 2007 and is based in Newton, Massachusetts, United States.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.

Genova is a biotechnology company focusing on the development and production of insulin.

Eucure Biopharma is a biotechnology company based in Beijing, China, specializing in the discovery and development of innovative immuno-oncology targeted antibodies. The company's primary focus is on immune checkpoints, with several products having advanced to the Chemistry, Manufacturing, and Controls (CMC) stage and clinical trials initiated in 2019. Eucure Biopharma aims to create antibody treatments that enhance the survival rates of patients with tumors, offering healthcare professionals more effective options for cancer treatment through the development of checkpoint and cancer growth inhibitors.

Eucure Biopharma is a biotechnology company based in Beijing, China, specializing in the discovery and development of innovative immuno-oncology targeted antibodies. The company's primary focus is on immune checkpoints, with several products having advanced to the Chemistry, Manufacturing, and Controls (CMC) stage and clinical trials initiated in 2019. Eucure Biopharma aims to create antibody treatments that enhance the survival rates of patients with tumors, offering healthcare professionals more effective options for cancer treatment through the development of checkpoint and cancer growth inhibitors.

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.

DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.

CARsgen Therapeutics, Ltd. is a clinical-stage immunotherapy company based in Shanghai, China, focused on developing chimeric antigen receptor T-cell (CAR-T) therapeutics for various cancers, including liver, lung, stomach, and brain cancers. The company specializes in CAR-T technology that enables T cells to target and destroy cancer cells by recognizing specific cell surface proteins. Notably, CARsgen’s therapies are designed to treat late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma. The company has also made significant advancements in clinical trials, having completed the world's first dose-ascending injection tests for HCC and exclusive tests for glioblastoma multiforme (GBM) in China. CARsgen collaborates with institutions such as the Shanghai Cancer Institute and Shanghai Renji Hospital, and is supported by prominent venture capital funding, positioning it to introduce innovative cancer treatments both in China and globally.

Jaguar Health develops and commercializes plant-based prescription medicines for urgent global health needs. Its product portfolio addresses multiple indications for gastrointestinal (GI) diseases, spanning multiple stages of development from preclinical to commercial approval.

Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. develops siRNA based preclinical drug candidates. Its products include QPI-1007, an ocular neuroprotectant. The company also develops siRNA-based cosmetic product for the prevention of hair loss. The company was founded in 2012 and is based in Kunshan, China.

Suzhou Ribo Life Science Co., Ltd. specializes in the development of nucleic acid drugs utilizing RNA interference (RNAi) technology, with a particular focus on treating liver diseases. Founded in 2007 and based in Kunshan, China, the company engages in various aspects of drug development, including drug discovery, siRNA design and screening, chemical modification, delivery technology, pharmacodynamics and pharmacokinetics studies, safety evaluation, and clinical trials. Suzhou Ribo Life Science offers siRNA therapeutics targeting conditions such as Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV. The company has established a strategic partnership with Quark Pharmaceuticals, Inc. to enhance its research and development capabilities.

Genova is a biotechnology company focusing on the development and production of insulin.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.